Neurology News

CHICAGO – Jennifer A. Frontera, MD, professor of neurology at NYU School of Medicine, discussed possible therapeutic strategies for those with long COVID who are experiencing neurological symptoms at ANA 2022.

CHICAGO — The neurological pathology of COVID-19 becomes more complex as symptoms persist and tends to affect the central nervous system more prominently, according to an expert at the American Neurological Association annual meeting.

CHICAGO — Alzheimer’s disease-related dementia among older adults is linked to a combination of neurodegenerative and vascular pathologies, according to a presenter at the 2022 American Neurological Association annual meeting.

CHICAGO – Felicia Chow, MD, MAS, a neuro-infectious specialist at the University of California, San Francisco, discussed the care and approach to neurological infections during a panel at ANA 2022.

CHICAGO – Ray Dorsey, MD, MBA, neurology professor at the University of Rochester, discusses a presentation he gave on environmental risk factors that may be associated with Parkinson’s disease at ANA 2022.

Reata Pharmaceuticals Inc. announced the FDA does not plan to hold an advisory committee meeting to discuss the company’s new drug application for an investigational therapeutic to treat Friedreich’s ataxia.

WASHINGTON — Some infants with in utero or early life exposure to SARS-CoV-2 had borderline to low developmental scores, a study found, and this was most common among babies born to mothers with symptomatic COVID-19.

MediCane Health Inc. announced recruitment of the first patient for its phase 2a study designed to assess the effects of cannabis oil in adults with probable Alzheimer’s disease who have limited or no response to antipsychotic medication.

Daily treatment with risdiplam over 24 months resulted in improved motor function and achievement of developmental motor milestones in infants with type 1 spinal muscular atrophy, according to a study published in The Lancet Neurology.

Empyrean Neuroscience Inc. has announced its launch as a genetic engineering company dedicated to developing fungi- and plant-based therapeutics for the treatment of neuropsychiatric and neurologic disorders.